Image of a climber swinging from a mouth of a cave

When you choose Brimonidine
don’t compromise Lumigan Logo

Consider ALPHAGAN® P 0.1% for the IOP-lowering efficacy equivalent to brimonidine 0.2% with improved tolerability.1,2

IOP=intraocular pressure.

Consider ALPHAGAN® P 0.1% for the IOP-lowering efficacy equivalent to brimonidine 0.2% with improved tolerability.1,2

IOP=intraocular pressure.


Designed to deliver IOP-lowering efficacy equivalent to brimonidine 0.2%2

  • Mean treated IOP equivalent to brimonidine 0.2% at all time points over 12 months
  • Mean IOP reduction from baseline up to 5.4 mm Hg (10 AM, Week 2 [peak effect])
  • Up to 23% mean IOP reduction from baseline
Up to
5.4 mm Hg

mean IOP reduction from baseline (10 AM, Week 2 [peak effect])2

IOP=intraocular pressure.

IOP=intraocular pressure.

Proposed Dual Mechanism of Action

ALPHAGAN® P 0.1%: Dual-action design in a single agent1

  • Thought to reduce aqueous humor production and increase uveoscleral outflow


Designed for an improved side-effect profile vs brimonidine 0.2%3

Significantly fewer treatment-related AEs and discontinuation rates due to AEs over 3 months with ALPHAGAN® P 0.1% vs brimonidine 0.2%

32% few patiences had treatement-related AEs and 42% fewer patiences discontinued use due to AEs 32% few patiences had treatement-related AEs

42% fewer patiences discontinued use due to AEs

Most common treatment-related AEs vs brimonidine 0.2%*

  • Allergic conjunctivitis—9.3% vs 9.2% (P=0.963)
  • Conjunctival hyperemia—7.0% vs 8.7% (P=0.501)
  • Oral dryness—1.4% vs 5.5% (P=0.019)

AE=adverse event.

*Incidence ≥5% in either group.


Starting patients on ALPHAGAN® P 0.1%1

ALPHAGAN® P 0.1% dosing is 1 drop three times daily, approximately 8 hours apart.

May be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure.

If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

Find resources for technicians and office staff

Access patient savings, pharmacy callback
guides, and patient counseling resources.

Instructions for applying eye drops

Step One Visual

Step 1

Wash your hands. Tilt your head back and look at the ceiling.

  • If you wear contact lenses, remove them first, then wait 15 minutes after using your eye drops to put them back into your eyes.
Step Two Visual

Step 2

Using your index finger, pull down your lower eyelid to form a pocket.

Step Three Visual

Step 3

Gently squeeze 1 drop into the pocket. Don’t let the bottle tip touch your eye, your fingers, or anything else.

Step Four Visual

Step 4

Gently close your eyes and lightly press on the inside corners of your eyes.

Step Five Visual

Step 5

Carefully blot away any excess liquid that may be on your skin.

Access and Savings

Eligible commercially-insured patients may pay as little as

$30 per 90-day prescription fill

That's as little as $10 a month for a 90-day supply

Patients can also call 1-833-DIAL-AYS (1-833-342-5297) or text SAVINGS to 72428.

Maximum savings limits apply; patient out-of-pocket expense will vary depending on insurance coverage. Offer valid for patients with commercial prescription insurance coverage and a valid prescription for LUMIGAN ® 0.01%, COMBIGAN®, or ALPHAGAN® P 0.1%. Offer not valid for patients enrolled in Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See At Your Service Savings Program Terms, Conditions, and Eligibility Criteria at

AYS Alerts: Msg and data rates apply. Msg frequency depends on user. Reply HELP for help; reply STOP to cancel. Consent to texts not required to sign up for offer. View our Mobile Terms & Conditions and Privacy Policy.

Need help with prior authorizations?

ABBVIEACCESS has you covered
Find Support


  1. ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% Prescribing Information.

  2. Data on file. Allergan, 2005; 190342-021.

  3. Data on file. Allergan, 2003; 190342-021.

  4. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension.Ther Clin Risk Manag. 2006;2(4):337-346.


ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.



Neonates and Infants (under the age of 2 years): ALPHAGAN® P is contraindicated in neonates and infants (under the age of 2 years).

Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.


Potentiation of Vascular Insufficiency: ALPHAGAN® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

Contamination of Topical Ophthalmic Products After Use: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.


Antihypertensives/Cardiac Glycosides: ALPHAGAN® P may reduce blood pressure. Use caution in patients on antihypertensives and/or cardiac glycosides.

CNS Depressants: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP-lowering effect. Use caution in patients on tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.

Monoamine Oxidase Inhibitors: Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Use caution in patients on MAO inhibitors, which can affect the metabolism and uptake of circulating amines.


Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

Please see accompanying full Prescribing Information or visit